Moree Melinda, Ewart Sarah
Malaria Vaccine Initiative, Program for Appropriate Technology in Health, Seattle, Washington 98107, USA.
Am J Trop Med Hyg. 2004 Aug;71(2 Suppl):248-52.
Recently licensed life-saving vaccines have experienced slow introduction and gradual uptake in the developing world. Policy challenges at the national level contribute to the delay in making new vaccines accessible to people in poor countries. The hurdles that delayed the introduction of other vaccines can provide guidance for navigating the policy challenges that face the introduction of a new malaria vaccine. When a malaria vaccine is licensed, national leaders will rely on available data and analyses to draw conclusions about which malaria interventions have the greatest potential for public health impact. Epidemiologic and economic analyses can help facilitate their decision-making. This article draws attention to the importance of research to inform policy decisions and to minimize delays in the introduction of a new malaria vaccine.
最近获得许可的救生疫苗在发展中国家的推广速度缓慢且采用过程渐进。国家层面的政策挑战导致新疫苗在贫穷国家难以惠及民众。此前其他疫苗推广过程中遇到的障碍可为应对新型疟疾疫苗推广面临的政策挑战提供指导。当疟疾疫苗获得许可时,国家领导人将依靠现有数据和分析来得出关于哪些疟疾干预措施对公共卫生影响潜力最大的结论。流行病学和经济分析有助于促进他们的决策。本文提请注意开展研究对于为政策决策提供信息以及尽量减少新型疟疾疫苗推广延迟的重要性。